Mohamad-Reza Aghanoori

Dr. Mohamad-Reza Aghanoori

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Biotechnology Advances
Verified
Journal Article
Closed access
SAShayan Amiri
Shayan Amiri
SDSanaz Dastghaib
Sanaz Dastghaib
MAMazaher Ahmadi
Mazaher Ahmadi
Parvaneh MehrbodParvaneh Mehrbod
Parvaneh Mehrbod
FKForough Khadem
Forough Khadem
Saeid GhavamiSaeid Ghavami
Saeid Ghavami

1 February 2019 in Molecular Metabolism
Verified
Journal Article
Open access
MAMohamad-Reza Aghanoori
Mohamad-Reza Aghanoori
DSDarrell R. Smith
Darrell R. Smith
SSShiva Shariati-Ievari
Shiva Shariati-Ievari
AAAndrew Ajisebutu
Andrew Ajisebutu
ANAnnee Nguyen
Annee Nguyen
PFPaul Fernyhough
Paul Fernyhough
Diabetic sensorimotor polyneuropathy (DSPN) affects approximately half of diabetic patients leading to significant morbidity. There is impaired neurotrophic growth factor signaling, AMP-activated protein kinase (AMPK) activity and mitochondrial function in dorsal root ganglia (DRG) of animal models of type 1 and type 2 diabetes. We hypothesized that sub-optimal insulin-like growth factor 1 (IGF-1) signaling in diabetes drives loss of AMPK activity and mitochondrial function, both contributing to development of DSPN. Age-matched control Sprague-Dawley rats and streptozotocin (STZ)-induced type 1 diabetic rats with/without IGF-1 therapy were used for in vivo studies. For in vitro studies, DRG neurons from control and STZ-diabetic rats were cultured and treated with/without IGF-1 in the presence or absence of inhibitors or siRNAs. Dysregulation of mRNAs for IGF-1, AMPKα2, ATP5a1 (subunit of ATPase), and PGC-1β occurred in DRG of diabetic vs. control rats. IGF-1 up-regulated mRNA levels of these genes in cultured DRGs from control or diabetic rats. IGF-1 treatment of DRG cultures significantly (P < 0.05) increased phosphorylation of Akt, P70S6K, AMPK and acetyl-CoA carboxylase (ACC). Mitochondrial gene expression and oxygen consumption rate (spare respiratory capacity), ATP production, mtDNA/nDNA ratio and neurite outgrowth were augmented (P < 0.05). AMPK inhibitor, Compound C, or AMPKα1-specific siRNA suppressed IGF-1 elevation of mitochondrial function, mtDNA and neurite outgrowth. Diabetic rats treated with IGF-1 exhibited reversal of thermal hypoalgesia and, in a separate study, reversed the deficit in corneal nerve profiles. In diabetic rats, IGF-1 elevated the levels of AMPK and P70S6K phosphorylation, raised Complex IV-MTCO1 and Complex V-ATP5a protein expression, and restored the enzyme activities of Complex IV and I in the DRG. IGF-1 prevented TCA metabolite build-up in nerve. In DRG neuron cultures IGF-1 signals via AMPK to elevate mitochondrial function and drive axonal outgrowth. We propose that this signaling axis mediates IGF-1-dependent protection from distal dying-back of fibers in diabetic neuropathy.

8 April 2022 in Science Advances
Verified
Journal Article
Open access
GSGlen Lester Sequiera
Glen Lester Sequiera
ASAbhay Srivastava
Abhay Srivastava
NSNiketa Sareen
Niketa Sareen
WYWeiang Yan
Weiang Yan
KAKeshav Narayan Alagarsamy
Keshav Narayan Alagarsamy
SDSanjiv Dhingra
Sanjiv Dhingra
A “Leap-of-Faith” approach is used to treat patients with previously unknown ultrarare pathogenic mutations, often based on evidence from patients having dissimilar but more prevalent mutations. This uncertainty reflects the need to develop personalized prescreening platforms for these patients to assess drug efficacy before considering clinical trial enrollment. In this study, we report an 18-year-old patient with ultrarare Leigh-like syndrome. This patient had previously participated in two clinical trials with unfavorable responses. We established an induced pluripotent stem cell (iPSC)–based platform for this patient, and assessed the efficacy of a panel of drugs. The iPSC platform validated the safety and efficacy of the screened drugs. The efficacy of three of the screened drugs was also investigated in the patient. After 3 years of treatment, the drugs were effective in shifting the metabolic profile of this patient toward healthy control. Therefore, this personalized iPSC-based platform can act as a prescreening tool to help in decision-making with respect to patient’s participation in future clinical trials.

18 December 2014 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
MAMohamad-Reza Aghanoori
Mohamad-Reza Aghanoori
BMBehnaz Mirzaei
Behnaz Mirzaei
MTMahmood Tavallaei
Mahmood Tavallaei
MiRNA Molecular Profiles in Human Medical Conditions: Connecting Lung Cancer and Lung Development Phenomena miRNA;medical conditions;lung cancer;lung development; MiRNAs are endogenous, single stranded ~22-nucleotide non-coding RNAs (ncRNAs) which are transcribed by RNA polymerase II and mediate negative post-transcriptional gene regulation through binding to 3'untranslated regions (UTR), possibly open reading frames (ORFs) or 5'UTRs of target mRNAs. MiRNAs are involved in the normal physiology of eukaryotic cells, so dysregulation may be associated with diseases like cancer, and neurodegenerative, heart and other disorders. Among all cancers, lung cancer, with high incidence and mortality worldwide, is classified into two main groups: non-small cell lung cancer and small cell lung cancer. Recent promising studies suggest that gene expression profiles and miRNA signatures could be a useful step in a noninvasive, low-cost and repeatable screening process of lung cancer. Similarly, every stage of lung development during fetal life is associated with specific miRNAs. Since lung development and lung cancer phenomena share the same physiological, biological and molecular processes like cell proliferation, development and shared mRNA or expression regulation pathways, and according to data adopted from various studies, they may have partially shared miRNA signature. Thus, focusing on lung cancer in relation to lung development in miRNA studies might provide clues for lung cancer diagnosis and prognosis.

1 November 2017 in Experimental Neurology
Verified
Journal Article
Closed access
MAMohamad-Reza Aghanoori
Mohamad-Reza Aghanoori
DSDarrell R. Smith
Darrell R. Smith
SCSubir Roy Chowdhury
Subir Roy Chowdhury
MSMohammad Golam Sabbir
Mohammad Golam Sabbir
NCNigel A. Calcutt
Nigel A. Calcutt
PFPaul Fernyhough
Paul Fernyhough

17 March 2022 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
MAMohamad-Reza Aghanoori
Mohamad-Reza Aghanoori
PAPrasoon Agarwal
Prasoon Agarwal
EGEvan Gauvin
Evan Gauvin
RNRaghu S. Nagalingam
Raghu S. Nagalingam
RBRaiza Bonomo
Raiza Bonomo
PFPaul Fernyhough
Paul Fernyhough
Aberrant insulin-like growth factor 1 (IGF-1) signaling has been proposed as a contributing factor to the development of neurodegenerative disorders including diabetic neuropathy, and delivery of exogenous IGF-1 has been explored as a treatment for Alzheimer’s disease and amyotrophic lateral sclerosis. However, the role of autocrine/paracrine IGF-1 in neuroprotection has not been well established. We therefore used in vitro cell culture systems and animal models of diabetic neuropathy to characterize endogenous IGF-1 in sensory neurons and determine the factors regulating IGF-1 expression and/or affecting neuronal health. Single-cell RNA sequencing (scRNA-Seq) and in situ hybridization analyses revealed high expression of endogenous IGF-1 in non-peptidergic neurons and satellite glial cells (SGCs) of dorsal root ganglia (DRG). Brain cortex and DRG had higher IGF-1 gene expression than sciatic nerve. Bidirectional transport of IGF-1 along sensory nerves was observed. Despite no difference in IGF-1 receptor levels, IGF-1 gene expression was significantly (P < 0.05) reduced in liver and DRG from streptozotocin (STZ)-induced type 1 diabetic rats, Zucker diabetic fatty (ZDF) rats, mice on a high-fat/ high-sugar diet and db/db type 2 diabetic mice. Hyperglycemia suppressed IGF-1 gene expression in cultured DRG neurons and this was reversed by exogenous IGF-1 or the aldose reductase inhibitor sorbinil. Transcription factors, such as NFAT1 and CEBPβ, were also less enriched at the IGF-1 promoter in DRG from diabetic rats vs control rats. CEBPβ overexpression promoted neurite outgrowth and mitochondrial respiration, both of which were blunted by knocking down or blocking IGF-1. Suppression of endogenous IGF-1 in diabetes may contribute to neuropathy and its upregulation at the transcriptional level by CEBPβ can be a promising therapeutic approach.